Recent trends in renal allograft survival rates indicate that increasing clinical experience has not resulted in increased graft survival. A major obstacle has been, and remains, early detection of rejection. The important role of both cellular and humoral immune mechanisms in rejection is becoming increasingly evident. Therefore, it is hoped that immunologic monitoring of the allograft recipient will be helpful in the early diagnosis of rejection. Although a number of assays for assessment of host immune response are available, their clinical relevance has not been clearly established. The following study was designed to ascertain the relationship between in vitro immunologic reactivity and clinical status of the human allograft recipient during the initial 3 months posttransplantation.
|Number of pages||3|
|Publication status||Published - 1 Dec 1977|
ASJC Scopus subject areas